Sign In
Buy CYCC
$6.37
+0 (+0%)
At Close: Dec 10, 2025
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript
09:04pm, Monday, 06'th Mar 2023
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Exe
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
02:15pm, Monday, 27'th Feb 2023 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
09:15am, Monday, 27'th Feb 2023
BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
02:15pm, Monday, 30'th Jan 2023 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
09:15am, Monday, 30'th Jan 2023
BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
02:15pm, Thursday, 05'th Jan 2023 GlobeNewswire Inc.
– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib –
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
02:15pm, Thursday, 15'th Dec 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
09:05pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma -
Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript
08:06pm, Wednesday, 09'th Nov 2022
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President & Chief Exec
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
02:40pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
01:15pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
09:15am, Thursday, 03'rd Nov 2022
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
01:15pm, Wednesday, 26'th Oct 2022 GlobeNewswire Inc.
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients Daily dosing of fadraciclib was well tolerated;
Cyclacel Hosting Research & Development Day
01:15pm, Monday, 24'th Oct 2022 GlobeNewswire Inc.
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-
